TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment
COMPLETION OF SERIES B FUNDRAISE
TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market.
TTS Pharma also announces the appointment of a new Executive Chairman, Paul Atherton, who brings with him Global Institutional and Public Market experience to the board.
TTS Pharma is a unique business with core competencies and partners in drug discovery, development, separation, purification and drug delivery, incorporating the supply chain management of cannabinoids, such as CBD. It is intending to provide a transparent and accountable supply chain that produces legal and regulated cannabis-derived active agents for R&D, Bulk Active ingredients and wholesale distribution of finished goods. TTS Pharma is committed to producing the highest quality, fully compliant CBD products for use in a large range of commercial segments, alongside a number of partners, after obtaining the requisite regulatory clearance.
The pre-established supply chain including both domestic and international partners enables the Company to legally supply various CBD products to a growing range of customers. In mid-2018, TTS Pharma commenced a comprehensive R&D sponsorship programme to extract the various cannabinoids, and then to consider their chemical properties and effects, in order to develop new products in both human and animal markets.
Paul Atherton commented:
“I am delighted to join TTS Pharma as Executive Chairman. Utilising existing in-house know-how, TTS Pharma represents a unique chance to develop and produce world class, novel products for the rapidly growing new industry of ethically-based, legal cannabis products. I see a long-term opportunity to establish cost and scale advantages, allowing this Company to flourish in this attractive, global emerging industry.”
TTS Pharma CEO, Mark Tucker added:
“It is a great privilege to lead a team of highly experienced pharmaceutical professionals building an exciting portfolio of technologies and products based on world class expertise and industry leading know-how. We are well placed to build on the scientific developments driving this rapidly growing industry and provide cannabinoid products of unparalleled quality and consistency. Since my early involvement in pre-clinical cannabinoid trials in 2003, TTS Pharma has grown extensively and is now producing and developing a range of innovative and safe cannabis-based products within existing legislation and the evolving regulatory framework.”
About Paul Atherton
Paul Atherton was until the end of 2017, the Chief Executive Officer and Chief Financial Officer of Heritage Oil Limited, which held both production and exploration assets around the world. The company was one of the largest oil and gas companies listed on the Main Board of the London Stock Exchange and a member of the FTSE 250, before being taken private for US$1.6 billion in 2014. During this time Paul executed significant fundraisings, mergers and acquisitions and the eventual privatisation, generating outstanding shareholder returns. Paul is a Chartered Accountant having qualified at Deloitte and worked in corporate finance at BDO.
About TTS Pharma Ltd
TTS Pharma is a private company, incorporated in England and Wales and established in 2012, with offices in London and Liverpool. The Company has an R&D business developing products and holds deep industry expertise in extraction, separation and manufacturing of Cannabinoids. The Company has begun sales of its highly purified cannabis related products and technologies. The company abides by all legal and regulatory requirements in the UK and elsewhere and expects to gain further permissions related to these products in due course.
TTS Pharma Ltd
Mark Tucker, CEO
Paul Atherton, Chairman
Sciad Communications Ltd
+44 203 7550571
Corporate Broker and Financial Advisor
The Life Sciences Division Ltd
Ms Alia Minhas MBA ACSI
+44 207 8741890
Dr. Navid Malik. PhD, MSc, MBA, ACSI
+44 207 8741890
Osborne Clarke LLP
Dr Janita Good, Partner Head of Lifescience and Healthcare
+44 207 1057042
Mark Dixon, Chief Thinking Officer
+44 207 5561093
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The We Company Q2 2019 Financial Results Conference Call19.8.2019 21:56:00 EEST | Press release
WeWork Companies LLC (the “Company”), with respect to its 7.875% Senior Notes due 2025 (the “Senior Notes”), will hold a conference call on Monday, August 26, 2019, at 12:00 P.M. Eastern Time for the benefit of certain qualified participants in order to discuss the Company’s financial results for the second quarter of 2019. Current holders and beneficial owners of the Senior Notes, bona fide prospective purchasers of the Senior Notes who are qualified institutional buyers (as defined in Rule 144A under the Securities Act of 1933) or non-U.S. persons (as defined in Regulation S under the Securities Act of 1933), securities analysts, and market-making financial institutions may gain access to the call information for the conference call by registering on the Company’s secure website at investors.wework.com. Additional information about the call (including dial-in number) will be provided on the secure website. Parties requesting access to the Company’s secure website will be required to
BAI Announces 2019 Global Innovation Award Finalists19.8.2019 20:50:00 EEST | Press release
BAI announced the finalists for the 2019 BAI Global Innovation Awards, the industry’s most prestigious awards program that celebrates transformative solutions in the financial services industry worldwide. Now in its ninth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. Through hundreds of applications, the Innovation Circle, a panel of global financial services innovation leaders who thoroughly review each application, determined the top submissions. The judges weigh each innovation on originality and impact on consumers and the industry. This year’s finalists showcase what leading financial services innovators in all regions of the world are doing to deliver new value to customers and employees, as well as improve efficiencies and profitability for their organizations. The 2019 BAI Global Innovation Awards finalists are: Best Application of Advanced Technology in a Product or Service Emirates NBD, Dubai, United Arab Emirate
Rimini Street Statement on U.S. Appeals Court Ruling19.8.2019 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today issued the following statement in response to the August 16, 2019 ruling by the U.S. Ninth Circuit Court of Appeals in the Oracle v. Rimini Street litigation which was filed in January 2010, went to trial in 2015, and has been on appeal since: “We are pleased that the Appeals Court again corrected legal errors in the District Court’s post-trial orders, adding to the Appeals Court’s and Supreme Court’s prior reversals in this case and refunds from Oracle totaling over $34 million. Oracle lost 23 of 24 claims it originally pursued against Rimini Street in this case, with the jury finding that Rimini Street engaged in “innocent infringement” on the remaining claim. Rimini Street had voluntarily stopped using the legacy processes that were found to be infringing before the 2015 trial
OpenGate Capital Announces Acquisition of Majority Interest in InRule Technology, Inc.19.8.2019 15:00:00 EEST | Press release
OpenGate Capital, a global private equity firm, announced today that it has acquired InRule Technology, Inc. (“InRule”), a market-leading decision management platform and business rules management system (BRMS). OpenGate is pleased to partner with the co-founders of InRule to continue innovation and leadership in the decision management market. This transaction marks the fifth investment completed in 2019 through OpenGate Capital’s second institutional fund. Financial terms were not disclosed. InRule software powers mission-critical decisions for enterprise and government customers. InRule provides an end-to-end, fully auditable platform that acts as a “single source of truth” for enterprises processing complex business rules and decision workflows. Its decision platform drives significant and quantifiable business value across a variety of use cases, including insurance eligibility, mortgage qualification, risk rating and fraud reduction, regulatory compliance, healthcare claims proce
Cogeco Peer 1 Changes Name to Aptum Technologies; Adds New Services to Enhance and Expand Hybrid Cloud Offerings19.8.2019 15:00:00 EEST | Press release
Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/ Susan Bowen, CEO of Aptum (Photo: Business Wire) “Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve compl
Slate Asset Management Announces Minority Investment From Goldman Sachs Asset Management’s Petershill Program19.8.2019 15:00:00 EEST | Press release
Slate Asset Management L.P. (Slate), a leading alternative asset management platform with a focus on real estate and real assets, today announced a passive, non-voting minority equity investment from Goldman Sachs Asset Management’s Petershill program, creating a strategic relationship with one of the world’s leading investment managers and positioning Slate for future success. The transaction will have no impact on the control or decision making of Slate. The day-to-day operations and management of Slate will remain unchanged. The investment provides capital that Slate will use to enhance its platform and increase its GP investments in current and future businesses and investment vehicles, further strengthening the firm’s alignment with its clients and investing partners. The investment accelerates Slate’s goal to build the leading independent alternative investment platform in real estate and real assets. As part of the transaction, Slate Founders Blair and Brady Welch have made a lo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom